Liquidia Corp. faced setbacks in 2024 due to FDA's backdated exclusivity grant to United Therapeutics, delaying YUTREPIA's launch until May 2025. YUTREPIA's superior clinical trial results and ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while the S&P 500 gained 19% since April. Brepocitinib shows promise for NIU ...

At the beginning of the STS session, an informal audience poll suggested more prostacyclin users in the room at a 60-40 show of hands. "Cost still pretty much favors the prostacyclin," observed ...